AAV serotype 2 vectors preferentially integrate into active genes in mice
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus serotype 2 (rAAV2) is a promising vector for gene therapy because it can achieve long-term stable transgene expression in animals and human subjects after direct administration of vectors into various target tissues. In the liver, although stable transgene expression primarily results from extrachromosomal vector genomes, a series of experiments has shown that vector genomes integrate into host chromosomes in hepatocytes at a low frequency. Despite the low integration efficiency, recent reports of retroviral insertional mutagenesis in mice and two human subjects have raised concerns about the potential for rAAV2-mediated insertional mutagenesis. Here we characterize rAAV2-targeted chromosomal integration sites isolated from selected or non-selected hepatocytes in vector-injected mouse livers. We document frequent chromosomal deletions of up to 2 kb at integration sites (14 of 14 integrations, 100%; most of the deletions were <0.3 kb) and preferred integration into genes (21 of 29 integrations, 72%). In addition, all of the targeted genes analyzed (20 of 20 targeted genes, 100%) were expressed in the liver. This is the first report to our knowledge on host chromosomal effects of rAAV2 integration in animals, and it provides insights into the nature of rAAV2 vector integration into chromosomes in quiescent somatic cells in animals and human subjects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Yet, follow-up studies indicated that 53-62% of rAAV integrations in the liver fused into actively-transcribed genes, and 3-8% into ribosomal DNA [247].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [247]
In the citing paper
“preclinical data suggest AAV integration events occur in a dose-dependent manner with a preference for integration at sites of active transcription, tissue-specific promoters are protective against oncogenesis.178, 179, 180”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [180]
In the citing paper
“This number is similar to multiple estimates of random integration of AAV8 from the literature.35”
From Adeno‐associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo†‡ (2010) · cites this paper as [35]
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Initial sequencing and comparative analysis of the mouse genome
Mouse Genome Sequencing Consortium (2002) · Nature · doi:10.1038/nature01262 · Cited by 7,187
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Large-scale analysis of the human and mouse transcriptomes
Su, A. I., Cooke, M. P., Ching, K. A., Hakak, Y., Walker, J. R., Wiltshire, T., Orth, A. P., Vega, R. G., Sapinoso, L. M., Moqrich, A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012025199 · Cited by 1,466
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022 · cited 1×
“jpg" NDATA ITEM> ]> Recombinant adeno-associated virus serotype 2 (rAAV2) is a promising vector for gene therapy because it can achieve long-term stable transgene expression in animals and human subjects after direct administration of vectors into various target tissue”
BackgroundSelf-citationOverturf, K., Al-Dhalimy, M., Tanguay, R., Brantly, M., Ou, C.-N., Finegold, M., & Grompe, M. (1996) · Nature Genetics · doi:10.1038/ng0396-266 · Cited by 549 · cited 1×
“Because there is a selective repopulation of stable genetically modified FAH-positive hepatocytes in HTI mouse liver”
BackgroundSelf-citationMurine leukemia induced by retroviral gene marking
Li, Z., Düllmann, J., Schiedlmeier, B., Schmidt, M., von Kalle, C., Meyer, J., Forster, M., Stocking, C., Wahlers, A., Frank, O., et al. (2002) · Science · doi:10.1126/science.1068893 · Cited by 525 · cited 1×
“Despite the low integration efficiency, recent reports of retroviral insertional mutagenesis in mic”
BackgroundNakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478 · cited 1×
“In the liver, although stable transgene expression primarily results from extrachromosomal vector genome”
BackgroundSelf-citationSOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data
Diehn, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg014 · Cited by 428 · cited 1×
“We assessed the transcriptional activity of each targeted gene using web-based public databases and browsers: NCBI UniGene, SOURC”
Method
Cited by
Items 201–300 of 400
Sustained Expression from DNA Vectors
Wong, S. P., Argyros, O., & Harbottle, R. P. (2014) · Advances in genetics · doi:10.1016/bs.adgen.2014.11.002 · Cited by 29
Liu, X., Liu, M., XUE, Z., Pan, Q., WU, L., Long, Z., Xia, K., LIANG, D., & Jia Hui, X. I. A. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02355.x · Cited by 27
Benn, S. C., Ay, İ., Bastia, E., Chian, R.-J., Celia, S. A., Pepinsky, R. B., Fishman, P. S., Brown, R. H., & Francis, J. W. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03459.x · Cited by 28
“2003; Lowenstein and Castro 2003), de novo mutations that can reactivate replication in previously replication-deficient viruses (Lundstrom 2003) and increased risk for developing cancer (Marshall 2002, 2003; Nakai et al. 2003).”
BackgroundStable transduction of large DNA by high-capacity adeno-associated virus/adenovirus hybrid vectors
Gonçalves, M. A. F. V., van der Velde, I., Knaän‐Shanzer, S., Valerio, D., & de Vries, A. A. F. (2004) · Virology · doi:10.1016/j.virol.2004.01.007 · Cited by 26
Application of nanotechnology in CAR-T-cell immunotherapy
Zeng, Q., Liu, Z., Niu, T., He, C., Qu, Y., & Qian, Z. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.107747 · Cited by 25
Park, Y. M., Woo, S., Lee, G. T., Ko, J., Lee, Y., Zhao, Z., Kim, H. J., Ahn, C. W., Soo, B., Kim, K., et al. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.708 · Cited by 25
Gene Therapy for Hemophilia: Progress to Date
Chapin, J. C., & Monahan, P. E. (2017) · BioDrugs · doi:10.1007/s40259-017-0255-0 · Cited by 26
“Furthermore, the majority of rAAV genomes remain extrachromosomal [145, 146], making genomic integration events infrequent [99, 147].”
BackgroundPark, C. W., Park, J., Kren, B. T., & Steer, C. J. (2006) · Genomics · doi:10.1016/j.ygeno.2006.04.007 · Cited by 25
“While viral vectors exhibit a clear preference for transcriptionally active regions as their target sites for integration [26,27], SB has displayed either no significant preference for actively transcribed regions in the host genome [21,24] or a very weak insertional bias toward transcriptional units [25].”
BackgroundGene therapies for mucopolysaccharidoses
Rossi, A., & Brunetti‐Pierri, N. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12626 · Cited by 25
“Although the fraction of AAV genomes that integrate into the host genome is small, 59 there is a hypothetical risk of germline transmission and cancer development due to AAV vector integration and secondary loss-or gain-of-function mutations in critical genes controlling the cell cycle.”
BackgroundHemophilia gene therapy: ushering in a new treatment paradigm?
George, L. A. (2021) · Hematology · doi:10.1182/hematology.2021000254 · Cited by 25
Keswani, S. G., Balaji, S., Le, L. D., Leung, A., Lim, F. Y., Habli, M. A., Jones, H. N., Wilson, J. M., & Crombleholme, T. M. (2012) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2012.00810.x · Cited by 26
Cunningham, S. C., Kok, C., Spinoulas, A., Carpenter, K. H., & Alexander, I. E. (2013) · Gene Therapy · doi:10.1038/gt.2013.51 · Cited by 24
AAV8 Gene Therapy Rescues the Newborn Phenotype of a Mouse Model of Crigler–Najjar
Greig, J. A., Nordin, J. M. L., Draper, C., Bell, P. L., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.185 · Cited by 25
“20 Random integrations of the AAV genome can occur, especially during growth, 21 leading to concerns over the risk of developing hepatocellular carcinoma (HCC).”
Gene therapy for inherited disorders of haematopoietic cells
Klein, C., & Baum, C. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200366 · Cited by 29
Buscara, L., Gross, D., & Danièle, N. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040258 · Cited by 22
Targeted integration of a rAAV vector into the AAVS1 region
Ward, P., & Walsh, C. (2012) · Virology · doi:10.1016/j.virol.2012.08.015 · Cited by 27
Gene therapy for inborn errors of liver metabolism
Brunetti‐Pierri, N., & Lee, B. (2005) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2005.07.015 · Cited by 21
“In the liver, usually only a fraction of the stably transduced genomes (typically 10%) integrate into the host genome and the transgene expression is derived mainly from the episomal AAV genome [69].”
BackgroundSchwab, M. E., & MacKenzie, T. C. (2021) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000655 · Cited by 22
Integration and the risk of liver cancer—Is there a real risk?
Kasimsetty, A., & Sabatino, D. E. (2024) · Journal of Viral Hepatitis · doi:10.1111/jvh.13915 · Cited by 21
Delivery of DNA-Based Therapeutics for Treatment of Chronic Diseases
Sussman, C., Liberatore, R. A., & Drozdz, M. M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040535 · Cited by 20
Singh, K., Fronza, R., Evens, H., Chuah, M., & VandenDriessche, T. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101365 · Cited by 19
DNA methylation of Sleeping Beauty with transposition into the mouse genome
Park, C. W., Kren, B. T., Largaespada, D. A., & Steer, C. J. (2005) · Genes to Cells · doi:10.1111/j.1365-2443.2005.00875.x · Cited by 19
Transposon-based vector systems for gene therapy clinical trials: challenges and considerations.
Meir, Y. J., & Wu, S. C. (2011) · PubMed · Cited by 22
Viral Hybrid Vectors for Somatic Integration - Are They the Better Solution?
Müther, N., Noske, N., & Ehrhardt, A. (2009) · Viruses · doi:10.3390/v1031295 · Cited by 21
Therapeutic Potential of Systemic Gene Transfer Strategy for Hypertension and Cardiovascular Disease
Sarkissian, S. D., & Raizada, M. K. (2007) · Elsevier eBooks · doi:10.1016/b978-0-323-03961-1.50040-4 · Cited by 17
Karnan, S., Ota, A., Konishi, Y., Wahiduzzaman, M., Hosokawa, Y., & Konishi, H. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1338 · Cited by 17
“Although the mechanism underlying enhanced random integration of the plasmid vector carrying 2A in comparison to IRES is unknown, this result might be related to the finding that AAV vectors are preferably integrated into gene-rich and transcriptionally active regions of the genome (53,54).”
BackgroundAAV-Mediated Gene Delivery to the Mouse Liver
Cunningham, S. C., & Alexander, I. E. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9065-8_12 · Cited by 17
Feasibility of gene therapy in Gaucher disease using an adeno-associated virus vector
Hong, Y. B., Kim, E. Y., Yoo, H., & Jung, S. (2004) · Journal of Human Genetics · doi:10.1007/s10038-004-0186-8 · Cited by 18
“However, the rAAV genome also preferentially integrated into chromosomal DNA (Nakai et al. 2003).”
BackgroundInfluentialCationic Liposome-Mediated Gene Delivery In Vivo
Liu, Y., Fong, S., & Debs, R. J. (2003) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(03)73034-1 · Cited by 17
Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials.
Metovic, J., Li, Y., Gong, Y., & Eichler, F. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00443 · Cited by 16
“However, AAV genome integration does occur, albeit at a much lower rate, in mice [215,216], dogs [217], primates [218], and humans [219,220].”
BackgroundCurrent and future prospects for hemophilia gene therapy
Ward, P., & Walsh, C. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1182859 · Cited by 18
“a preference for integration into active genes [59], especially into the albumin and alpha-fetoprotein genes.”
BackgroundGene Therapy - Developments and Future Perspectives
Kang, C. (2011) · InTech eBooks · doi:10.5772/748 · Cited by 16
“In summary, although rAAV can achieve stable integration in certain cell types, this integration is random as for retroviral vectors and can cause mutations (Nakai et al., 2003) and tumor development (Donsante et al., 2007).”
BackgroundLiver-directed gene-based therapies for inborn errors of metabolism
Piccolo, P., Rossi, A., & Brunetti‐Pierri, N. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1817375 · Cited by 16
Long‐term gene expression and metabolic control exerted by lentivirus‐transduced pancreatic islets
He, Z., Wang, F., Kumagai‐Braesch, M., Permert, J., & Holgersson, J. (2006) · Xenotransplantation · doi:10.1111/j.1399-3089.2006.00274.x · Cited by 16
Primer on Medical Genomics Part X: Gene Therapy
Russell, S. J., & Peng, K.-W. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.11.1370 · Cited by 17
Lemmens, M., Dorsheimer, L., Zeller, A., & Dietz, Y. (2024) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2024.503767 · Cited by 16
Wang, Z., Troilo, P. J., Griffiths, T. G., Harper, L. B., Barnum, A. B., Pacchione, S. J., Pauley, C. J., Lebron, J. A., Wolf, J. J., & Ledwith, B. J. (2021) · Gene Therapy · doi:10.1038/s41434-021-00278-2 · Cited by 15
Systemic delivery of therapeutics to neuronal tissues: a barrier modulation approach
Campbell, M., Ozaki, E., & Humphries, P. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2010.490554 · Cited by 15
“Finally, AAV vectors maintain persistent expression of shRNAs in vivo and the vector genomes can be modified to aid in tissue-specific delivery or to allow inducible expression of shRNAs [35,36].”
BackgroundBalaggan, K. S., Durán, Y., Georgiadis, A., Thaung, C., Barker, S. E., Buch, P. K., MacNeil, A., Robbie, S. J., Bainbridge, J. W., Smith, A. J., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.194 · Cited by 18
Zhang, S., Wu, J., Wu, X., Xu, P., Tian, Y., Miaoying, Y., Liu, X., Dong, X., Wolf, F., Li, C., et al. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-8856 · Cited by 15
Adeno-associated viral delivery of a metabolically regulated insulin transgene to hepatocytes
Kozlowski, M., Olson, D. E., Rubin, J. E., Lyszkowicz, D., Campbell, A. G., & Thulé, P. M. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.04.011 · Cited by 17
Fink, D. J. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00358-3 · Cited by 15
AAV vectors for gene correction.
Cathomen, T. (2004) · PubMed · Cited by 16
Opportunities for gene therapy in preventing vein graft failure after coronary artery bypass surgery
Baker, A. H., Yim, A. P. C., & Wan, S. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00494.x · Cited by 14
Gene therapy in Parkinson?s disease
Eberhardt, O., & Schulz, J. B. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0947-x · Cited by 15
“In addition to episomal replication, vector integration occurs randomly or, in the presence of the rep gene product, on chromosome 19q; this process prefers active genes (Nakai et al. 2003).”
Intrathymic AAV delivery results in therapeutic site-specific integration at TCR loci
Calabria, A., Cipriani, C., Spinozzi, G., Rudilosso, L., Esposito, S., Benedicenti, F., Albertini, A., Pouzolles, M., Luoni, M., Giannelli, S. G., et al. (2023) · Blood · doi:10.1182/blood.2022017378 · Cited by 23
Self-citationGene Therapy for Pituitary Tumors
Seilicovich, A., Pisera, D. A., Sciascia, S. A., Candolfi, M., Puntel, M., Xiong, W., Jaita, G., & Castro, M. G. (2005) · Current Gene Therapy · doi:10.2174/156652305774964721 · Cited by 13
“The AAV vectors are considered non-integrating vectors although they can sometimes integrate into the host genome within active genes [Nakai et al., 2001; Nakai et al., 2003].”
BackgroundGene therapy for Parkinson’s disease using recombinant adeno-associated viral vectors
Muramatsu, S., Tsukada, H., Nakano, I., & Ozawa, K. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.5.663 · Cited by 14
“Although chromosomal rearrangements in association with rAAV integration have been observed in a transformed cell line [27] and in regenerating hepatocytes [28], rAAV is more commonly present in vivo as duplex, circular and head-to-tail concatemers, most of which are episomal in non-dividing cells in the absence of se…”
BackgroundIsenmann, S., Schmeer, C. W., & Kretz, A. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.01.005 · Cited by 15
Yoshioka, Y., Abe, T., Wakusawa, R., Moriya, T., Mochizuki, S., Saigo, Y., Saito, T., Murata, H., Tokita, Y., Iseya, T., et al. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-0398 · Cited by 13
“Although accumulating evidence suggests that most of the transduced AAV DNA is not integrated into the host genome, some is integrated and induces deletions in the chromosome.(30,31) We did not find any changes in the cell morphology and cell viability of the rat IPE cells at successive passages after transduction.”
BackgroundLong-Term Safety of GDNF Gene Delivery in the Retina
Wu, W., Lai, C., Chen, S., Sun, M., Xiao, X., Chen, T.-L., Lin, K., Kuo, S.-W., & Tsao, Y. (2005) · Current Eye Research · doi:10.1080/02713680591005922 · Cited by 12
Mutagenesis and Oncogenesis by Chromosomal Insertion of Gene Transfer Vectors
Baum, C. F., Kustikova, O. S., Modlich, U., Li, Z., & Fehse, B. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.ft-181 · Cited by 12
Minno, G. D., Castaman, G., CRISTOFARO, R. D., Brunetti‐Pierri, N., Pastore, L., Castaldo, G., Trama, U., & Minno, M. N. D. D. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101011 · Cited by 12
Minno, G. D., Spadarella, G., Maldonato, N. M., Lucia, N. D., Castaman, G., CRISTOFARO, R. D., Santoro, C., Peyvandi, F., Borrelli, A., Lupi, A., et al. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101118 · Cited by 11
Gene therapy approaches for the treatment of Parkinson's disease
DASS, B., & Kordower, J. H. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)84045-0 · Cited by 11
Recombinant Adeno-Associated Viral Vector Reference Standards
Moullier, P., & Snyder, R. O. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-386509-0.00015-6 · Cited by 11
More than chemotaxis: A new anti-tumor DC vaccine modified by rAAV2-SLC
Liang, C., Ye, S., Zhong, C., Zheng, N., Bian, W., Sun, R., Chen, J., Li, R., Zhou, S. Y., & Liu, Y. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.03.026 · Cited by 10
Kren, B. T., Yin, W., Key, N. S., Hebbel, R. P., & Steer, C. J. (2007) · Endothelium · doi:10.1080/10623320701346932 · Cited by 10
Fonck, C., Su, C., Arens, J., Koziol, E., Srimani, J. K., Henshaw, J., Tuyl, A. V., Chandra, S. A. M., Vettermann, C., & O’neill, C. A. (2022) · Gene Therapy · doi:10.1038/s41434-022-00318-5 · Cited by 10
Miller, D. G. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-370-7_13 · Cited by 10
Applications of Sleeping Beauty transposons for nonviral gene therapy
Liu, H., & Visner, G. A. (2007) · IUBMB Life · doi:10.1080/15216540701435722 · Cited by 9
“Integrating viral vectors including the ‘safest’ vector AAV shows a propensity to integrate into active genes and promoter regions ( 27 ).”
BackgroundAdachi, K., & Nakai, H. (2011) · InTech eBooks · doi:10.5772/24265 · Cited by 9
“The DNA-PKcs or Artemis-independent NHEJ might be those involving ATM and/or MRN (Cataldi & McCarty, 2010; Choi et al., 2006; Duan et al., 2003; Inagaki et al., 2007b; Nakai et al., 2003b; Sanlioglu et al., 2000; Song et al., 2001).”
InfluentialSelf-citationGene therapy works in animal models of rheumatoid arthritis so what!
van de Loo, F. A. J., Geurts, J., & van den Berg, W. B. (2006) · Current Rheumatology Reports · doi:10.1007/s11926-006-0070-y · Cited by 9
“Recombinant AAV2 integration in mouse liver and cultured human cells was favored in actively transcribed genes, which can lead to small deletions of host chromosomal DNA [ 50 ].”
BackgroundViral Vectors for Gene Therapy
Linden, R. M., & Berns, K. I. (2010) · Wiley eBooks · doi:10.1002/9780470688618.taw0274 · Cited by 9
Adeno-associated virus vectors for human gene therapy
Chen, H. (2015) · World Journal of Medical Genetics · doi:10.5496/wjmg.v5.i3.28 · Cited by 9
Kang, S.-H. L., Levings, P. P., Andersen, F. F., Laipis, P. J., Berns, K. I., Zori, R., & Bungert, J. (2004) · Genes to Cells · doi:10.1111/j.1365-2443.2004.00788.x · Cited by 9
“Adeno-associated virus is considered to be safe because it does not cause strong immune reactions and the DNA of recombinant viruses used in gene therapy experiments often remain episomal (Flotte 2004), although some data suggest that AAV serotype 2 integrates preferentially into transcriptionally active regions in th…”
BackgroundSite-Specific Integration into the Human Genome: Ready for Clinical Application?
Recchia, A., & Mavilio, F. (2006) · Rejuvenation Research · doi:10.1089/rej.2006.9.446 · Cited by 8
Mutagenesis and Oncogenesis by Chromosomal Insertion of Gene Transfer Vectors
Baum, C. F., Kustikova, O. S., Modlich, U., Li, Z., & Fehse, B. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.ft-190 · Cited by 8
Paiboonsukwong, K., Ohbayashi, F., Shiiba, H., Aizawa, E., Yamashita, T., & Mitani, K. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1382 · Cited by 8
“Large-scale characterization of integration sites for AAV vectors in mouse liver and normal human fibroblasts showed a significant preference for intragenic regions and CpG islands, suggesting inherent risks for insertional mutagenesis by AAV [29,30].”
BackgroundEngineering Baculo- and Lentiviral Vectors for Enhanced and Targeted Gene Delivery
Kaikkonen, M. U. (2008) · Cited by 8
Design of Lentivirally Expressed siRNAs
Liu, Y. P., & Berkhout, B. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-119-6_13 · Cited by 8
Cho, M., Jung, K., Kim, S., Kim, I., Kim, M., Shin, M., Lee, H., Park, K. I., & Jang, J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0057-8 · Cited by 7
Enabling Precision Medicine with CRISPR-Cas Genome Editing Technology: A Translational Perspective
Ilahibaks, N. F., Hulsbos, M. J., Lei, Z., Vader, P., & Sluijter, J. P. G. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_20 · Cited by 11
Toxicologic Neuropathology of Novel Biotherapeutics
Bangari, D. S., Lanigan, L. G., Cramer, S. D., Grieves, J. L., Meisner, R., Rogers, A. B., Galbreath, E. J., & Bolon, B. N. (2023) · Toxicologic Pathology · doi:10.1177/01926233241230542 · Cited by 7
“42,46,112 Certain AAV serotypes and differences in expression cassette engineering (such as a tissue-or cellular-directed promoter) have an enhanced affinity for neural expression.”
BackgroundKacherovsky, N. A., Harkey, M. A., Blau, C. A., Giachelli, C. M., & Pun, S. H. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks213 · Cited by 7
“In comparison with integrating viruses, such as human immunodeficiency virus type 1 (HIV-1) and murine leukemia virus (MLV) (29,30), SB shows lower integration preference for intragenic regions (10,25,31).”
BackgroundKuroda, M., Saitō, Y., Aso, M., & Yokote, K. (2018) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c17-00786 · Cited by 7
Lessons from neuronal HIF1a: Understanding its role in ventilatory acclimatization to hypoxia
Khuu, M. A. (2020) · The Journal of Physiology · doi:10.1113/jp280205 · Cited by 7
“This possibility is supported by evidence showing AAV2 vectors more readily integrate into actively expressed genes (Nakai et al., 2003).”
BackgroundLiver-directed gene therapy for dyslipidemia and diabetes
Oka, K., & Chan, L. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0033-6 · Cited by 7
“Even though the integration of AAV vector genome into the host genome is biased toward active genes [ 16 ], the tumorigenic potential resulting from insertional mutagenesis is minimized in liver-directed gene therapy for reasons given previously.”
BackgroundFlory, E., Walter, M., Closson-Carella, V., Celis, P., Schuessler‐Lenz, M., & Reischl, I. G. (2025) · Human Gene Therapy · doi:10.1177/10430342251366314 · Cited by 6
Gene-Therapy Delivery Strategies in Cardiology
Müller, O. J., Ksienzyk, J., & Katus, H. A. (2008) · Future Cardiology · doi:10.2217/14796678.4.2.135 · Cited by 7
“However, it has been shown that AAV vectors are able to integrate into active genes [28].”
BackgroundThanou, M., Waddington, S. N., & Miller, A. D. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00009-2 · Cited by 8
Russell, C. B., Vettermann, C., Agarwal, S., Witt, E., Clark, W. T., Arens, J., Fronza, R., Obrochta, K. M., Kasprzyk, T., Robinson, T. M., et al. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.236 · Cited by 5
Vectors for gene therapy: A place for DNA transposon
Chénais, B. (2013) · Open Journal of Genetics · doi:10.4236/ojgen.2013.32a1001 · Cited by 6
“Most of the integrating viral vectors have integration site preferences leading to an integration site bias that may explain some adverse effects such as gene silencing or activation of cancer-related genes [51-54].”
BackgroundPrenatal gene therapy for the early treatment of genetic disorders
Abi-Nader, K. N., Rodeck, C. H., & David, A. L. (2008) · Expert Review of Obstetrics & Gynecology · doi:10.1586/17474108.4.1.25 · Cited by 5
AAV Vector-Based Gene Therapy, Progress and Current Challenges
Kuranda, K., & Mingozzi, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_5 · Cited by 5
Gene Therapy in Tyrosinemia: Potential and Pitfalls
Carter, S., & Doyon, Y. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_21 · Cited by 6
The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art
Minno, G. D., Spadarella, G., Calcaterra, I. L., Castaman, G., Simioni, P., CRISTOFARO, R. D., Santoro, C., Peyvandi, F., & Minno, M. N. D. D. (2024) · Bleeding Thrombosis and Vascular Biology · doi:10.4081/btvb.2024.144 · Cited by 4
AAV-mediated genome editing is influenced by the formation of R-loops
Puzzo, F., Crossley, M. P., Goswami, A., Zhang, F., Pekrun, K., Garzon, J. L., Cimprich, K. A., & Kay, M. A. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.09.035 · Cited by 4
Self-citationA Scalable Cell-Loading System for Non-Viral Gene Delivery and Other Applications
Fratantoni, J. C., Dzekunov, S. M., Wang, S., & Liu, L. L. (2004) · BioProcessing Journal · doi:10.12665/j36.fratantoni · Cited by 4
Genome Editing for Neuromuscular Diseases
Ousterout, D. G., & Gersbach, C. A. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-3509-3_4 · Cited by 4
Brunetti‐Pierri, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817344-2.00030-7 · Cited by 5
Adeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · ASM Press eBooks · doi:10.1128/9781555819217.ch37 · Cited by 5
Gene therapy using AAV vectors
Ozawa, K. (2007) · Drug Delivery System · doi:10.2745/dds.22.643 · Cited by 4
Alméciga-Díaz, C. J., Sáenz, H., & Luis Alejandro Barrera, A. (2023) · Revista de la Academia Colombiana de Ciencias Exactas Físicas y Naturales · doi:10.18257/raccefyn.30(117).2006.2280 · Cited by 4
Kubisch, H. M., Gagliardi, C., Romero, D. G., Bunnell, B. A., & Ratterree, M. S. (2008) · Molecular Reproduction and Development · doi:10.1002/mrd.20901 · Cited by 4
“Integration appears to be independent of the AAVS1 site, but is concomitant with deletions at the integration site and may occur preferentially in actively transcribed genes, a phenomenon that has been demonstrated in cultured cells and in vivo tissue (Miller et al., 2002; Nakai et al., 2003).”
Psychiatric Applications of Viral Vectors
Green, T. A., & Nestler, E. J. (2006) · Elsevier eBooks · doi:10.1016/b978-012397632-1/50015-0 · Cited by 5
RAAVioli: A comprehensive approach to characterizing AAV vector integrations and rearrangements
Cipriani, C., Rudilosso, L., Dalwadi, D. A., Masseroli, M., Grompe, M., Montini, E., Calabria, A., & Cesana, D. (2025) · Molecular Therapy Advances · doi:10.1016/j.omta.2025.201659 · Cited by 5
“17 Despite the positive safety results obtained in clinical trials, the discovery that AAV can integrate into the host cell genome raises safety concerns, as a single intravenous systemic administration of AAV can transduce hundreds of millions of liver cells.”
Self-citationIsmail, A. M., Witt, E., Bouwman, T., Clark, W. T., Yates, B., Franco, M., & Fong, S. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101294 · Cited by 4
“20,60 Therefore, after examining vector integration within 100 kb of the TSS of cancer-associated genes, we next determined the relative proximity of these integrations within 10 kb of a TSS for both protein-coding and cancer-associated genes.”
New Vectors for Stable and Safe Gene Modification
Martín, F., Benabdellah, K., Cobo, M., Munoz, P., Anderson, P. O., & Miguel, G. (2011) · InTech eBooks · doi:10.5772/10622 · Cited by 3
“In summary, although rAAV can achieve stable integration in certain cell types, this integration is random as for retroviral vectors and can cause mutations (Nakai et al., 2003) and tumor development (Donsante et al.”
BackgroundLentiviral vectors as the delivery vehicles for transduction into iPSCs
Kantor, B., & Chiba‐Falek, O. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85766-6.00005-x · Cited by 7
Metadata
- Authors
- Nakai, H., Montini, E., Fuess, S., Storm, T. A., Grompe, M., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Oregon Health & Science University (US)
- Corresponding author
- Kay, Mark A
- Venue
- Nature Genetics
- Published
- 2003-06-01
- Volume
- 34
- Issue
- 3
- Pages
- 297-302
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2171427593
- Cited by
- 392
- References
- 29
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 13 · 2023: 12 · 2022: 11 · 2021: 11 · 2020: 18 · 2019: 8 · 2018: 10 · 2017: 10 · 2016: 8 · 2015: 13 · 2014: 8 · 2013: 7 · 2012: 19
- FWCI
- 22.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- AAV2, rAAV2, chromosomal integration, insertional mutagenesis, gene therapy vectors, hepatocytes, liver, somatic cells, transgene expression
- MeSH terms
- Dependovirus, Animals, Base Sequence, Cell Line, Chromosome Deletion, Chromosomes, Female, Genes, Genetic Vectors, Humans, Mice, Inbred C57BL, Molecular Sequence Data, Plasmids, Sequence Homology, Nucleic Acid, Transduction, Genetic, Genetic Therapy, Virus Integration, Gene Transfer Techniques, Transgenes, Hepatocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.